Sobre este pódcast
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
262 episodios · science
BioSpace
Último episodioThe supply chain fault lines of modern pharma
Sobre este pódcast
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Episodios recientes
- Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease9 sept · 20 min
- Breaking borders: Building biotech scale in Benelux3 sept · 19 min
- Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals2 sept · 20 min
- Fragile X at a turning point: Breaking through the clinical bottleneck27 ago · 19 min
- Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealed26 ago · 23 min
- Rewriting the rules of CMV prevention20 ago · 20 min
- Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more19 ago · 19 min
- The Italian inflection point: Clinical strength, culture and capital13 ago · 19 min
- Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight12 ago · 19 min
- Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms11 ago · 23 min
podlinkr.com/es/biospace
Para un cartel o una diapositiva.